Advertisement

Topics

Latest "Kolltan Pharmaceuticals, Inc." News Stories

15:37 EDT 18th March 2019 | BioPortfolio

Here are the most relevant search results for "Kolltan Pharmaceuticals, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Kolltan Pharmaceuticals, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Kolltan Pharmaceuticals, Inc. for you to read. Along with our medical data and news we also list Kolltan Pharmaceuticals, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Kolltan Pharmaceuticals, Inc. Companies for you to search.

Showing "Kolltan Pharmaceuticals" News Articles 1–25 of 8,500+

Monday 18th March 2019

The Philadelphia Adult Congenital Heart Center Earns Accreditation from the Adult Congenital Heart Association (ACHA)

Joint program between Children’s Hospital of Philadelphia and Penn Medicine is the first Delaware Valley institution to have earned ACHA Adult Congenital Heart Disease (ACHD) Accreditation MEDIA, Pa. (PRWEB) March 18, 2019 In recognition of its expertise in serving adults with congenital heart disease (CHD), the Philadelphia Adult Congenital Heart Center has received accreditation from the Adul...


Digital Therapeutics: A threat or opportunity to pharmaceuticals

Reporter and Curator: Dr. Sudipta Saha, Ph.D.   Digital Therapeutics (DTx) have been defined by the Digital Therapeutics Alliance (DTA) as “delivering evidence based therapeutic interventions to patients, that are driven by software to prevent, manage or treat a medical disorder or disease”. They might come in the form of a smart phone or computer […]

HAEMATO AG: Preliminary Results 2018

DGAP-News: HAEMATO AG / Key word(s): Preliminary Results 18.03.2019 / 15:14 The issuer is solely responsible for the content of this announcement. Corporate News of HAEMATO AG: HAEMATO AG was able to achieve an EBITDA of EUR 10.0m for the fiscal year 2018 according to preliminary IFRS financial statements. HAEMATO AG, Berlin (ISIN: DE0006190705), achieved consolidated sales of EUR 27...


Aerpio Pharmaceuticals ($ARPO) Shares Plummet after Lead Candidate Fails Phase IIb Diabetic Retinopathy Trial: http://ow.ly/YP7h30o5s7G pic.twitter.com/55YIatvyNI

Aerpio Pharmaceuticals ($ARPO) Shares Plummet after Lead Candidate Fails Phase IIb Diabetic Retinopathy Trial: http://ow.ly/YP7h30o5s7G  pic.twitter.com/55YIatvyNI

A fish-oil-derived drug sold by Amarin Pharmaceuticals helped prevent not only initial cardiovascular events but also second and third heart attacks, according to a new analysis. #ACC19 https://buff.ly/2TP13XC 

A fish-oil-derived drug sold by Amarin Pharmaceuticals helped prevent not only initial cardiovascular events but also second and third heart attacks, according to a new analysis. #ACC19 https://buff.ly/2TP13XC 

Aerpio Shares Plummet after Lead Candidate Fails Phase IIb Diabetic Retinopathy Trial

Aerpio Pharmaceuticals acknowledged the failure of its lead pipeline candidate in a Phase IIb trial in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR), triggering a selloff by investors that sent the company’s shares plunging by more than 70% in early market trading. AKB-9778 failed the Phase IIb TIME-2b trial (NCT03197870) by missing its […] The post Aerpio ...

Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate

A fish-oil-derived drug sold by Amarin Pharmaceuticals helped prevent not only initial cardiovascular events but also second and third heart attacks, according to a new analysis. #ACC19

Théa and OliX Announce Collaboration to Develop RNAi Therapies for the Treatment of AMD

- License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel treatment for dry and wet age-related macular degeneration. - OliX to receive an upfront payment of 2 million euro, and eligible to receive milestones, plus royalty for the development and commercialization in

Novo Nordisk settles US patent litigation case on Victoza® (liraglutide) with Teva

Bagsværd, Denmark, 18 March 2019 - Novo Nordisk today announced that a settlement between Novo Nordisk and Teva Pharmaceuticals USA, Inc. (Teva) has been reached on the US patent litigation case for Victoza® (liraglutide). Consequently, Teva is licensed to launch a generic version of Victoza® as of 22 December 2023. Under certain circumstances Teva could launch a generic ...

ArunA Bio Appoints Al Medwar as Executive Vice President, Corporate and Commercial Development

ArunA Bio, a leader in the development of exosomes and exosome therapeutics for the treatment of neurodegenerative disorders, today announced the appointment of Al Medwar as Executive Vice President, Corporate and Commercial Development. Mr. Medwar joins the company and its leadership team contributing over 30 years of pharmaceutical industry experi...

Karuna raises $68m to develop neurology drug KarXT

Karuna Therapeutics has raised $68 million to further develop its neurology drug KarXT, which is in phase 2 clinical development for acute psychosis in patients with schizophrenia. Formerly known as Karuna Pharmaceuticals, the company is an affili...

Arrowhead Pharmaceuticals Files IND for Pivotal Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference ...

Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies

Respiratory Syncytial Virus (RSV) Human Challenge Study with EDP-938 ARGON-1 Study in Non-alcoholic Steatohepatitis (NASH) with EDP-305 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today ann...

Aerpio Pharmaceuticals Announces Results From TIME-2b Study of AKB-9778 in Diabetic Retinopathy

TIME-2b Study Did Not Meet the Primary Endpoint of 2-Step Reduction in DRSS Score Conference Call and Webcast Today, March 18th at 8:30 a.m. EDT Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced top-line...

Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a Phase 2 clinical trial...

Bicycle Therapeutics Appoints Pierre Legault as New Director and Board Chairman

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today the appointment of Pierre Legault, MBA, CPA, as a Director and Chairman of the Board of Directors. Mr. Legault brings to Bicycle more than 35 years of executive leadership experi...

Actinogen Medical - Differentiated treatment for Alzheimer's disease

Edison Investment Research - Pharmaceuticals & healthcare - Actinogen Medical: Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment ...

Sunday 17th March 2019

Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning

SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning. ...

GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M

CARLSBAD, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that GW Research Ltd. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105,000,000.  GW was awarded ...

Paratek Pharmaceuticals Announces Management Change

BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced that Douglas Pagán, Chief Financial Officer, has resigned, effective April 5, 2019, to join an early-stage biopharmaceutical company. Mr. Pagán has entered into a consu...

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

Phase 3 RECOVERY Trial of Tonmya® for the Treatment of PTSD Initiated and Enrolling Topline Data Expected First Half 2020 NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix, or the Company), a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological p...

5 Top Weekly NASDAQ Biotech Stocks: Index Back in the Green

Soleno Therapeutics, Atossa Genetics, Agile Therapeutics, Syros Pharmaceuticals and Conatus Pharmaceuticals were last week's top gainers. The post 5 Top Weekly NASDAQ Biotech Stocks: Index Back in the Green appeared first on Investing News Network.

Actinogen Medical (ACW) - Differentiated treatment for Alzheimer’s disease

Edison Investment Research - Pharmaceuticals & healthcare - Actinogen Medical: Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem to treat cognitive impairment that occurs in chronic neurodegenerative diseases. Xanamem® is a selective 11β-HSD1 inhibitor that is able to cross the blood-brain barrier and target excess brain cortisol, which has been assoc...

Saturday 16th March 2019

H. Lundbeck AS LUN Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09112018] Prices from USD $250

SummaryH. Lundbeck AS Lundbeck, a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing and marketing of pharmaceuticals for the treatment of the central nervous system CNS diseases including psychiatric and neurological disorders. Its products are indicated for the treatment of diseases such as Alzheimer's disease, depression, Parkinson's disease, schizophren...

Warum GW Pharmaceuticals im Februar um 20,5 % gestiegen ist

Was ist passiert? Die Aktien von GW Pharmaceuticals (WKN:693692) stiegen letzten Monat nach Daten von S&P Global Market Intelligence um 20,5 %. Am ersten Tag im März, stiegen sie um weitere 3,1 %. ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks